N/A N=3 Transmagnetic Stimulation Pilot in Primary Progressive Aphasia
Primary Progressive Aphasia
Primary: Connectivity Measures of the Left TGd, 55b, and STV Parcellations at Baseline and Post-treatment — -.06; .03; -.01 correlation
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 Flortaucipir PET Imaging in Subjects With FTD
Frontotemporal Dementia
Primary: Qualitative Evaluation of Flortaucipir PET Scans — 0; 0; 13 Participants
Phase 2 N=28 Effects of Tolcapone on Frontotemporal Dementia
Frontotemporal Lobar Degeneration
Primary: Reaction Time on the N-back Cognitive Test (0-back Condition) — 7935; 8322 milliseconds
Phase 2 N=16 Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
Frontotemporal Dementia (FTD)
Primary: Change in Agitation and Aggression as Measured by the Neuropsychiatric Inventory Scale (NPI) — 7.14; 5.75 score on a scale
N/A N=16 Support Via Technology: Living and Learning With Advancing FTD
Caregivers Burnout · Frontotemporal Dementia
Primary: Revised Memory and Behavior Problems Checklist (RMBPC) — 28.5; 25.2; 16.6; 15.8 units on a scale
Phase 4 N=81 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
Frontal Lobe Dementia · Frontotemporal Lobe Dementia · Semantic Dementia
Primary: Change in Neuropsychiatric Inventory (NPI) — -1.9; 0.3 units on a scale
Phase 2 N=33 A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Frontotemporal Dementia
Primary: Severity of TEAEs — 43; 58; 84; 4 TEAEs (all)
Phase 1 N=161 Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia
Primary Progressive Aphasia · Behavioral Variant of Frontotemporal Dementia · Frontotemporal Dementia, Behavioral Variant
Primary: Proportion of PPA Subjects That Showed Elevated Tau PET Binding Compared to Normal Controls — 3; 0; 17; 0 Participants
Phase 2 N=28 Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Alzheimer's Disease · Frontotemporal Dementia
Primary: Qualitative Amyloid Image Assessment — 2; 1; 8; 4 participants
N/A N=24 Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy
CTE · TBI (Traumatic Brain Injury)
Primary: Distribution Volume Ratio (DVR) — 1.30; 1.39; 1.26; 1.34 Distribution Volume Ratio (DVR) — p=<0.02
N/A N=31 Improving Self-Care of Behavioral Variant Frontotemporal Dementia Caregivers
Behavioral Variant of Frontotemporal Dementia · Caregiver Stress Syndrome
Primary: Change From Baseline in the Self-Care Inventory (SCI) — 71.4; 66.4; 80.4; 68.9 score on a scale
N/A N=45 Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia
Alzheimer's Disease · Frontotemporal Dementia, Behavioral Variant
Primary: Change in Clinical Disease Severity (CDR) — -0.1; 0.0; 0.0; 0.0 score on a scale
N/A N=6 Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia
Frontotemporal Dementia · Right Sided Cerebral Hemisphere Cerebrovascular Accident
Primary: Change in Social-Cognitive Functioning — 34.6; 34.6; 35.3; 34.6 Number Correct
N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
N/A N=37 tDCS Intervention in Primary Progressive Aphasia
Primary Progressive Aphasia · MCI · FTD
Primary: Absolute Percent Change in Written Naming (Trained Items) — 39.4; 28.4; 33.1; 20.0 absolute percent change
Phase 2 N=30 Tau Imaging of Chronic Traumatic Encephalopathy
Chronic Traumatic Encephalopathy
Primary: Tau Protein Uptake.. — 1.1871; 1.1652; 1.5910 SUVr
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Phase 2 N=41 18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
Chronic Traumatic Encephalopathy
Primary: Flortaucipir Visual Read as CTE Biomarker — 23; 11; 5; 0 Participants — p=0.2959
Phase 3 N=156 18F-AV-1451 Autopsy Study
Alzheimer's Disease
Primary: Primary Outcome 1: Diagnostic Performance of Individual Readers (NFT Score) — 97.4; 68.0; 92.3; 92.0 percentage of cases correctly identified
N/A N=8 Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy
Primary Progressive Aphasia · PPA
Primary: Change in Accuracy of Naming Trained Verbs (0 to 15, Higher Scores Reflect Better Naming Abilities) as Assessed by Object and Action Naming Battery (OANB) — 2.3; 2.05…
Phase 2 N=125 Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
Alzheimer Disease · Cognitive Decline
Primary: Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans — 1.09 standardized uptake value ratio
N/A N=10 TMS for the Treatment of Primary Progressive Aphasia
Logopenic Variant Primary Progressive Aphasia · Non-fluent Variant Primary Progressive Aphasia · Semantic Variant Primary Progressive Aphasia
Primary: Changes in Language as Measured Through the Boston Naming Test (BNT) — 1.8; 2.5; 0.063; 0.5 Items
Phase 1 N=29 Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
Progressive Supranuclear Palsy · Corticobasal Degeneration
Primary: Flortaucipir Imaging in PSP, CBD and Healthy Volunteers — 1.17; 1.12; 1.03; 1.15 standardized uptake value ratio (SUVr)
Phase 4 N=127 Corticolimbic Degeneration and Treatment of Dementia
Dementia
Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095
Phase 3 N=239 Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline
Progressive Cognitive Decline
Primary: Percentage of Subjects Who Undergo a Hypothetical Change in Clinical Diagnosis and Physician Management Plan After Obtaining a Negative Florbetapir F 18 PET Scan…
N/A N=18 Treating Primary Progressive Aphasia (PPA) Using tDCS
Primary Progressive Aphasia
Primary: Western Aphasia Battery Aphasia Quotient (WAB-AQ) — 74.4; 76.5; 72.5; 76.0 scores on a scale — p=<.05
Phase 3 N=223 Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
Alzheimer's Disease
Primary: Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline — 36; 31; 27; 37 Participants — p=0.067
Phase 2 N=179 Clinical Evaluation of Flortaucipir F 18
Alzheimer's Disease · Traumatic Brain Injury · Depression
Primary: Number of Participants With Adverse Events Related to Flortaucipir Administration — 0; 3; 0; 3 Participants
Phase 3 N=205 Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
Alzheimer Disease
Primary: Risk Ratio for AD Symptom Progression on CDR-SB — 119; 43; 10; 5 Participants — p=0.0313
Phase 3 N=1,111 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560